News | February 09, 2023
JB Pharma records revenue growth of 32% to Rs. 793 Cr in Q3 FY23
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
The company completed paracetamol capacity expansion by 1,800 MTPA and the company is now focusing on frugal manufacturing practices to reduce raw material cost and expand margins
During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 crore Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
The Durezol brand and generic had US sales of approximately US $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA
SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
Products offered on a not-for-profit basis to the 45 lower-income countries now include the full portfolio for which Pfizer has global rights.
Subscribe To Our Newsletter & Stay Updated
